Clinical Report: Maternal NSAID Use During Pregnancy and Kidney Disease in Children

Overview

This meta-analysis reveals a significant association between maternal NSAID use during pregnancy and an increased risk of kidney disease in children. The findings suggest that exposure during the second and third trimesters is particularly concerning.

Background

Kidney diseases in children can lead to severe health complications and represent a growing global health concern. With over 50% of pregnant women reportedly using NSAIDs for various symptoms, understanding the potential risks associated with prenatal exposure is crucial for maternal and child health. This study aims to clarify the relationship between maternal NSAID use and the risk of kidney disease in offspring.

Data Highlights

Key Findings

• Maternal NSAID use during pregnancy is associated with a 36% increased risk of kidney disease in children.
• Adjusted analyses indicate an even higher risk (OR 2.40) for kidney disease linked to NSAID exposure.
• Specific risks are noted for NSAID use during the second (OR 1.17) and third trimesters (OR 1.10).
• Over 50% of pregnant women use NSAIDs, highlighting the importance of understanding their effects.
• Further high-quality studies are needed to establish causality and control for confounding factors.

Clinical Implications

Healthcare providers should be cautious when prescribing NSAIDs to pregnant women, particularly during the second and third trimesters. The findings underscore the need for alternative pain management strategies and careful monitoring of maternal NSAID use to mitigate potential risks to offspring.

Conclusion

This meta-analysis provides evidence of a significant association between prenatal NSAID exposure and kidney disease in children, emphasizing the need for further research to clarify causality and inform clinical guidelines.

Related Resources & Content

1. FDA, FDA, 2020 -- FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid
2. Gestational Exposure to Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Childhood - PMC, PMC, 2026 -- Gestational Exposure to Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Childhood
3. Frontiers, Frontiers, 2026 -- Prenatal NSAIDs Exposure and Childhood Kidney Disease: A Systematic Review and Meta-Analysis
4. Drug Safety — NSAID Use and Associated Upper Gastrointestinal Complications
5. conexiant — Tylenol in Pregnancy: New Review
6. Drug Safety — An Overview of Non-Therapeutic and Supplementary Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
7. Drug Safety — Evaluating Cardiovascular Risks Associated with Non-steroidal Anti-inflammatory Medications: Implications for Clinical Practice
8. Drug Safety — NSAID Use and Associated Upper Gastrointestinal Complications
9. conexiant — Tylenol in Pregnancy: New Review
10. Drug Safety — An Overview of Non-Therapeutic and Supplementary Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid | FDA
12. Gestational Exposure to Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Childhood - PMC
13. Frontiers | Prenatal NSAIDs Exposure and Childhood Kidney Disease: A Systematic Review and Meta-Analysis